J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn’s Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success
Johnson & Johnson (J&J, NYSE: JNJ) announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA (guselkumab) across clinically important subgroups of adults with Crohn's disease with…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
